What are the indications, recommended settings, and contraindications for using Adaptive Servo‑Ventilation (ASV) in patients with central or complex sleep apnea?

Adaptive Servo-Ventilation (ASV) for Central Sleep Apnea

Adaptive servo-ventilation is the most effective therapy for suppressing central sleep apnea and Cheyne-Stokes respiration, and modern ASV devices show no mortality signal when used appropriately based on left ventricular ejection fraction. 1

Indications for ASV

Primary Indications (After CPAP Failure)

• Treatment-emergent central sleep apnea (TE-CSA) is the most common indication for ASV, representing the majority of cases in sleep clinics, and should be initiated after an adequate CPAP trial fails to control central events. 1, 2, 3

• Opioid-induced central sleep apnea responds highly effectively to ASV without additional restrictions beyond standard cardiac screening, following a failed CPAP trial. 1, 2

• Idiopathic (primary) central sleep apnea warrants ASV when CPAP proves ineffective at controlling central events and symptoms persist. 1, 2

• Post-stroke central sleep apnea can be treated with ASV after CPAP failure in symptomatic patients. 1

Heart Failure Patients: Ejection Fraction-Based Algorithm

The safety and appropriateness of ASV in heart failure depends entirely on left ventricular ejection fraction (LVEF): 1, 2

LVEF > 45% (HFpEF - Preserved Ejection Fraction)

• ASV is safe and effective after failed CPAP trial with no restrictions beyond standard monitoring. 1, 2
• This represents the safest heart failure population for ASV therapy. 1

LVEF 30-45% (HFmrEF - Mid-Range Ejection Fraction)

• ASV may be initiated ONLY in expert centers with close monitoring and after optimization of guideline-directed medical therapy for heart failure. 1, 2
• Requires failed CPAP trial before consideration. 1, 2
• This intermediate-risk group demands specialized expertise in both sleep medicine and cardiology. 1

LVEF < 30% (Severe Systolic Dysfunction)

• ASV is contraindicated except in palliative care settings at experienced centers when no alternative therapies are feasible and symptoms are severe. 1, 2
• Should only be considered after optimal medical management, failed CPAP, and failed oxygen therapy. 1, 2
• The SERVE-HF trial showed increased cardiovascular and all-cause mortality in this population with older ASV algorithms. 4

Contraindications

Absolute Contraindications

• Heart failure with LVEF ≤ 45% and predominant central sleep apnea when used outside expert centers or without proper patient selection. 1, 5, 2
• This contraindication applies to approximately 9-16% of potential ASV candidates depending on clinical setting. 3

Relative Contraindications

• Severe systolic heart failure (LVEF < 30%) except in palliative contexts at specialized centers. 1, 2
• Inadequate trial of CPAP before ASV initiation—CPAP must be attempted first across all etiologies. 1, 5, 2
• Suboptimal treatment of underlying disease—cardiac therapy must be optimized before initiating ASV. 1, 2

Recommended Settings and Titration

Initial Setup

• ASV devices measure minute ventilation or airflow continuously to calculate a target ventilation level, then adjust inspiratory positive airway pressure (IPAP) dynamically to maintain stable breathing. 6

• Expiratory positive airway pressure (EPAP) should be titrated to eliminate any obstructive component, as ASV treats both central and obstructive events. 1, 6

• Pressure support is delivered anticyclic to the patient's respiratory pattern with a backup rate to suppress central apneas and Cheyne-Stokes breathing. 6

Modern vs. Older Algorithms

• Modern ASV devices (post-ADVENT-HF era) use variable EPAP and adaptive pressure support, contrasting with older SERVE-HF devices that employed fixed EPAP and minimal pressure support. 1, 2

• Current ASV algorithms show no harm signal in recent randomized controlled trials and observational cohorts, including no class effect on mortality in heart failure patients. 1, 5, 2

Titration Goals

• Target apnea-hypopnea index (AHI) < 5-10 events/hour with elimination of central events and any residual obstructive events. 1

• Adequate nightly usage (≥4 hours/night for >70% of nights) is associated with better outcomes, including reductions in major adverse cardiac events in observational cohorts. 1, 2

Treatment Algorithm

Step 1: Optimize Underlying Disease

• Maximize guideline-directed medical therapy for heart failure, adjust or discontinue offending medications (especially opioids if possible), and manage neurological conditions. 5, 2

Step 2: Initial CPAP Trial

• Begin CPAP for all central sleep apnea patients regardless of etiology to treat any coexisting obstructive component and stabilize breathing patterns. 5, 2
• Confirm CPAP responsiveness with sleep testing and review of device-generated data after an adequate trial period. 5

Step 3: Add Acetazolamide if CPAP Fails

• Acetazolamide is the first pharmacologic option for persistent central events after CPAP failure, applicable across primary, medication-induced, treatment-emergent, and other medical-condition-related CSA. 5, 2
• Monitor electrolytes at 2-4 weeks in heart failure patients due to arrhythmia risk. 2

Step 4: Consider ASV Based on LVEF

• Apply the ejection fraction-based algorithm detailed above to determine ASV appropriateness. 1, 2
• Bilevel PAP with backup rate is an alternative to ASV across all etiologies after CPAP failure. 5, 2
• Never use bilevel PAP without backup rate—it offers no benefit over CPAP and may worsen central events. 5, 2

Clinical Outcomes and Evidence

Efficacy on Sleep Parameters

• ASV is superior to medical therapy alone, acetazolamide, non-invasive ventilation, neural stimulation, and nocturnal oxygen for suppressing central sleep apnea and Cheyne-Stokes respiration. 1

• Mean AHI decreases to approximately 6-7 events/hour on ASV therapy in heart failure patients. 4

Patient-Reported Outcomes

• Quality of life improves significantly with ASV across various forms of central sleep apnea, including treatment-emergent CSA with and without cardiovascular disease. 1, 7

• Daytime sleepiness decreases in observational cohorts, with median Epworth Sleepiness Scale reductions of 2-3 points. 7

• Functional Outcomes of Sleep Questionnaire (FOSQ) scores increase by approximately 0.7-0.9 points, indicating meaningful improvement in daily functioning. 7

Cardiovascular Outcomes

• Meta-analysis of four randomized controlled trials shows no effect on mortality in heart failure patients with reduced ejection fraction and central sleep apnea, contradicting the SERVE-HF findings. 5

• Observational cohorts demonstrate reductions in major adverse cardiac events in subgroups with longer nightly usage, preserved ejection fraction, or predominant obstructive events. 1, 2

• Current ASV devices have no negative effect on hard cardiovascular endpoints based on recent evidence from randomized trials and real-world registries. 1

Common Pitfalls and How to Avoid Them

Pitfall 1: Using ASV Without Prior CPAP Trial

• Always attempt CPAP first to address obstructive components and assess central event persistence before escalating to ASV. 1, 5, 2

Pitfall 2: Initiating ASV in LVEF ≤ 45% Outside Expert Centers

• Restrict ASV in mid-range ejection fraction (30-45%) to specialized centers with expertise in both sleep medicine and heart failure management. 1, 2
• Avoid ASV entirely in severe systolic dysfunction (LVEF < 30%) except in palliative settings. 1, 2

Pitfall 3: Neglecting Underlying Disease Optimization

• Optimize heart failure therapy, adjust medications, and manage comorbidities before attributing symptoms solely to central sleep apnea. 1, 2

Pitfall 4: Misclassifying Hypopneas as Central vs. Obstructive

• Esophageal pressure monitoring is required for accurate differentiation, as hypopnea-dominant patterns can be misclassified without this technique. 8

Pitfall 5: Ignoring Adherence and Follow-Up

• Monitor device downloads, ventilatory parameters, and patient-reported outcomes routinely to ensure adequate usage and therapeutic response. 5
• Re-assess AHI, sleep quality, cardiac function, and adverse effects at follow-up visits. 2

Special Populations

Treatment-Emergent CSA (TE-CSA)

• TE-CSA accounts for 80% of ASV indications in respiratory sleep centers and occurs after an appropriate CPAP treatment period. 3
• Reducing inspiratory positive airway pressure (IPAP) can resolve TE-CSA in some patients, suggesting that excessive tidal volume from IPAP increments may contribute to central event onset. 9

Opioid-Induced CSA

• ASV is highly effective without additional restrictions beyond standard cardiac screening after CPAP failure. 1, 2
• Opioid-induced CSA involves depression of central respiratory drive, a mechanism distinct from the heightened chemosensitivity seen in cardiac-related cases. 8

High-Altitude CSA

• Low-flow supplemental oxygen is first-line for symptomatic patients, with acetazolamide as an alternative. 2
• Many patients acclimate spontaneously; definitive therapy is descent to lower altitude. 2

Monitoring and Safety

Routine Monitoring Parameters

• Device-generated data including AHI, central apnea index, leak, and nightly usage hours. 5
• Patient-reported outcomes such as Epworth Sleepiness Scale and quality-of-life questionnaires. 1, 7
• Echocardiographic parameters and exercise capacity in heart failure patients. 1

Safety Considerations in Heart Failure

• Electrolyte monitoring at 2-4 weeks when acetazolamide is added to ASV therapy due to arrhythmia risk. 2
• Close cardiovascular follow-up in patients with LVEF 30-45% receiving ASV at expert centers. 1, 2

Key Takeaway for Clinical Practice

ASV should be reserved for patients with symptomatic central sleep apnea who fail CPAP, with safety determined by left ventricular ejection fraction: unrestricted use in LVEF > 45%, expert-center-only use in LVEF 30-45%, and contraindicated in LVEF < 30% except for palliative care. 1, 2